Terminal complement complex C5b-9 and C5b assay in sera of COVID-19 patients with different disease severities
Objective: The aim of this study is to find out the link between the involvement of complement activation in the inflammatory reactions in COVID-19 patients, the deterioration of the clinical status and development of sever COVID-19 in those patients. Methodology: The study included 274 COVID-19 pat...
主要な著者: | Asmaa Nasr El-Din, Kamal Ata |
---|---|
フォーマット: | 論文 |
言語: | English |
出版事項: |
Zagazig University, Faculty of Medicine
2022-10-01
|
シリーズ: | Microbes and Infectious Diseases |
主題: | |
オンライン・アクセス: | https://mid.journals.ekb.eg/article_261883_a3edd5e4a63df2c2e4e6c70bfc4b4951.pdf |
類似資料
-
Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
著者:: Zvi Fishelson, 等
出版事項: (2019-04-01) -
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
著者:: Wioleta M. Zelek, 等
出版事項: (2020-12-01) -
Biomarkers of the Complement System Activation (C3a, C5a, sC5b-9) in Serum of Patients before and after Liver Transplantation
著者:: Marta Budkowska, 等
出版事項: (2023-07-01) -
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
著者:: Guo-Qing Tang, 等
出版事項: (2023-08-01) -
Complement inhibition by anti-C5 antibodies - from bench to bedside and back again
著者:: Swiss Medical Weekly
出版事項: (2007-07-01)